IMA202-101

· Immatics US, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMA202-101, covering 2025-02-04 to 2025-02-04. Get the full timeline:

Most recent: Clinical Trial Update: TCR-engineered T Cells in Solid Tumors: IMA202-101 [Phase 1]